Current issues in ketamine uropathy  by Tong, Yat-Ching
lable at ScienceDirect
Urological Science 26 (2015) 174e175Contents lists avaiUrological Science
journal homepage: www.urol-sci .comEditorial commentCurrent issues in ketamine uropathyIn this issue of Urological Science, Ma and Chu1 have given a
timely review on the current knowledge and burden of ketamine
cystitis. Since 2007, when the earliest reports appeared on bladder
dysfunction and cystitis associated with recreational ketamine
use,2,3 our understanding of the problem has grown, but not sub-
stantially. Several fundamental questions remain unanswered.
One important lesson we have learned from clinical experience
is that the disease is not conﬁned to the bladder, but may involve
the upper urinary tract. In one study,4 computed tomography urog-
raphy revealed that up to 44% of patients had hydronephrosis. Sha-
hani et al2 ﬁrst coined the term “ketamine-induced ulcerative
cystitis”; however, the simpler term “ketamine cystitis” has gained
greater popularity. Neither of these two terms can adequately
describe the possible extent of the disease. Another term has also
been proposed: “ketamine-induced uropathy.”5 Thus, a consensus
is needed for naming the disease. For the time being, I would think
the term “ketamine uropathy” (KU) is simple and appropriate.
Research into KU pathophysiology suggests the involvement of
various pathways and mechanisms such as inﬂammation, nerve
dysfunction, epithelial barrier impairment, immunological reaction,
microvascular injury, oxidative stress, and apoptosis.6e9 However, it
is more important to know how the disease begins than how it pro-
gresses. The disease process of KU may bear many similarities to
other chronic inﬂammatory or pain disorders, but its etiology should
be unique. The toxic effects of ketamine and its metabolites norket-
amine and hydroxynorketamine have been postulated as the initi-
ating event.10 However, this assumption has one drawback: if
toxicity is the sole cause, how dowe explain that only approximately
one-quarter of users experience urinary symptoms?11 Of course, one
possible explanation is that there are ketamine dose or duration
thresholds that must be achieved for toxic effects to occur. However,
such evidence is lacking to date. Therefore, future epidemiology
studies should aim to analyze the relationship between various pa-
rameters of ketamine usage and the occurrence of KU. We should
look with more interest for heavy ketamine users who do not have
KU. If indeed such people do exist, we should study them carefully
to understand the underlying protective mechanisms.
Another point worth pondering concerning KU etiology is that
to date the disease is reported only in relation to recreational use,
not clinical use. Long-term ketamine administration is clinically
provided to patients with chronic pain or psychological disorders.
The adverse effects of ketamine reported in clinical studies include
psychedelic symptoms (e.g., hallucinations, memory defects, panic
attacks), nausea or vomiting, somnolence, cardiovascular stimula-
tion and, in a minority of patients, hepatoxicity.12 No reports of
KU have been reported in patients with clinical ketamine use. Streethttp://dx.doi.org/10.1016/j.urols.2015.08.003
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).ketamine is not legally manufactured and we are understandably
unsure of its composition. There could be some harmful impurities.
Therefore, it is imperative to compare the chemical composition of
ketamine from different sources. We may otherwise overlook the
real culprit.
Advanced cases of KU are difﬁcult to treat because few effective
measures are available. Some patients ultimately need urinary
diversion or dialysis. By contrast, milder cases are more treatable,
provided the patient can stop using ketamine. Quitting may unfor-
tunately be difﬁcult.
One of my patients is a young female sex worker who experi-
ences severe pain during intercourse. My prescriptions did not
help; therefore, her only solution has been to use ketamine during
work for temporary escape from the physical reality.
Some KU patients come to the hospital. However, after they
leave, they enter an environment where there is no escape from ke-
tamine. These patients need more than lifestyle modiﬁcation; they
need life modiﬁcation. Therefore, KU is more than a medical prob-
lem; it is also a social problem. It is a good sign that some govern-
ments and nongovernmental organizations are taking the
initiatives to tackle the problem.
After joining a Christian fellowship, a male patient of mine suc-
cessfully quit his 14-year ketamine snorting habit. He achieved a
dramatic improvement in symptoms. The disease can be and
should be terminated. When the abuse stops, the disease stops.
We hope KU will someday be just an historical term in our medical
literature.
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